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ABSTRACT 
 
Biological Activity of Garcinia kola seeds on Hepatitis C 
 
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV). 
According to the World Health Organization, hepatitis C infections affect 
between 130-150 million people worldwide.  It is a major cause of liver cirrhosis 
and liver cancer, and approximately 500,000 people die from hepatitis C 
infections or related complications each year.  Although new treatments are 90% 
effective at curing chronic hepatitis C infections, they cost tens of thousands of 
dollars. Available treatments are incredibly cost prohibitive, especially 
considering that the regions most affected by hepatitis C are Africa and central 
and eastern Asia (“Hepatitis C”).  This creates a need for the investigation of 
more cost-effective HCV treatments in order to better serve the populations with 
the highest prevalence of HCV infections. 
The seeds of Garcinia kola, often referred to as bitter kola, have been used 
as a folk medicine in Africa for hundreds of years.  The seeds have cultural 
significance to some Nigerian tribes, such as the Yoruba and Ibo tribes, and they 
are frequently used in naming and marriage ceremonies (Adebisi 2004).  In 
traditional African medicinal practices, the seeds have been used as an 
aphrodisiac, a stimulant, an antidiarrheal, a treatment for throat infections, and a 
cough suppressant (Okoko 2009).  However, there has been peer-reviewed 
research revealing antihepatotoxic, antibacterial, and antioxidant activity present 
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in the constituents of the Garcinia kola seed as well (Iwu 1987; Akinpelu; 
Okoko).   
In this study, the seeds of Garcinia kola were ground up and gravity 
filtered with several solvents of differing polarities.  The filtrates of these gravity 
filtrations were then dried using rotary evaporation, fractionated using solid phase 
extraction with silica cartridges or column chromatography, and dried again using 
rotary evaporation.  After being dried, the fractions were weighed and sent off for 
a DCT bioassay to test for biological activity against hepatitis C.   
The results of the bioassay revealed one Garcinia kola fraction with 
significant biological activity against hepatitis C.  The hexane crude extract of 
Garcinia kola at a concentration of 10 μg/ml exhibited an inhibitory effect on the 
HCV antigen and rRNA of 39.09% and 27.56%, respectively.  In an attempt to 
purify this crude extract, column chromatography with silica cartridges was 
performed using a 10% gradient of hexane: ethyl acetate.  These 10 new samples 
were then dried using rotary evaporation.  Nuclear magnetic resonance (NMR) 
spectroscopy was then performed on the resulting fractions in an attempt to 
characterize the structure of the molecule containing the hepatitis C biological 
activity.   
However, the fractionation by column chromatography with silica 
cartridges of the crude hexane extract failed to completely separate the Garcinia 
kola into its individual constituents.  Therefore, there were multiple molecules 
being displayed in each of the NMR spectra, making the identity of any individual 
constituent of the hexane crude extract impossible to deduce.  Due to this 
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complication, the results of the NMR and the identity of the molecule containing 
hepatitis C biological activity is incomplete.  HPLC would be needed to 
completely purify it.  However, one possible candidate for the biological activity 
against hepatitis C seen in the bioassay is kolaviron, a mixture of three chemically 
similar biflavonoids: kolaflavanone, Garcinia biflavonone 1 (GB1), and Garcinia 
biflavonone 2 (GB2).  
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I.  Introduction 
  
i. Purpose 
 
The purpose of this thesis is to explore the biological activity between 
Garcinia kola and hepatitis C infections with the goal that the information 
presented may eventually lead to drug discovery.  This was accomplished through 
extensive fractionation of the Garcinia kola seeds followed by DCT bioassay of 
the resulting fractions to determine activity and NMR to determine structure.   
 
ii. Background 
 
 Garcinia kola, more commonly known as bitter kola, is a flowering plant 
that grows in the rainforests of central and western Africa.   It is dicotelydenous 
and grows in the humid lowland rainforests from Sierra Leone to Angola.  It has a 
slow rate of growth and a long gestation period before fruiting, which discourages 
many farmers from choosing to cultivate it.  Between July and October of each 
season, the mature Garcinia kola tree produces reddish fruits, each of which 
contains between 2 and 4 large seeds.  The Garcinia kola seed has cultural 
significance to some Nigerian tribes, such as the Yoruba and Ibo tribes, and it is 
frequently used in naming and marriage ceremonies (Adebisi 2004).  
 In addition to its cultural uses, Garcinia kola has been heralded for its 
supposed various medicinal qualities.  For its traditional medical uses, the seed is 
believed to be an aphrodisiac, a stimulant, and a cough suppressant. It is also used 
for its alleged effects as a treatment for diarrhea, throat infections, and bronchitis 
(Okoko 2009).  The efficacy of these traditional uses has been largely unexplored; 
however, Garcinia kola has a notable presence in research studies for its 
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antihepatotoxic (Iwu 1987), antibacterial (Akinpelu), and antioxidant (Okoko 
2009) properties.   
 Due to the nature of this thesis, the published antihepatotoxic properties of 
Garcinia kola are of particular interest.  There appear to be three known principal 
biflavonoid constituents in Garcinia kola seeds that are believed to be responsible 
for its antihepatotoxicity: kolaflavanone, Garcinia biflavonone 1 (GB1), and 
Garcinia biflavonone 2 (GB2) (Akintonwa and Essein 1990).  These three 
molecules are very chemically similar, and the mixture of the three is collectively 
referred to as kolaviron.  In one study, pretreatment of either kolaviron, GB1, or 
GB2 had significant positive effects on the survival rates of rats who were 
administered doses of four known hepatotoxins: carbon tetrachloride, 
galactosamine, α-amanitin, and phalloidin (Iwu 1987).  Another study showed 
that kolaviron was also had antihepatotoxic effects on the hepatotoxin 
paracetamol (Akintonwa and Essein 1990). 
 
 
Figure 1: Structure of kolaviron. For Garcinia biflavonone 1, R1 is OH and R2 is H. For Garcinia 
biflavonone 2, R1 is OH and R2 is OH. For kolaflavonone, R1 is OCH3 and R2 is OH.  
  
In one study completed by Maurice M. Iwu in 1987, kolaviron extracted 
from the Garcinia kola seed had antihepatotoxic effects on four separate 
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hepatotoxins. Carbon tetrachloride, galactosamine, α-amanitin, and phalloidin all 
have different modes of action for their hepatotoxicity and all affect different 
parts of the cell.  Carbon tetrachloride is associated with damage to the rough 
endoplasmic reticulum, phalloidin harms the plasma membrane of liver cells, α-
amanitin inhibits eukaryotic RNA-polymerase B, and galactosamine causes 
necrosis of the liver and severely elevates the levels of three liver enzymes: 
glutamic oxaloacetic transaminase (GOP), glutamic pyruvic transaminase (GPT), 
and glutamate dehydrogenase (GLDH). This elevation can serve as a measure of 
the damage done to the liver by hepatotoxins. Kolaviron was able to significantly 
lower the concentrations of these liver enzymes in rats poisoned with carbon 
tetrachloride and galactosamine.  The protection of kolaviron against 
galactosamine poisoning is particularly important, because the hepatotoxicity 
caused by galactosamine resembles the lesions that are caused by viral hepatitis 
(Akintonwa and Essein 1990).  
When the kolaviron, GB1, or GB2 was administered via intraperitoneal 
injection, they were not significantly more effective than the control saline 
solution at reducing damage from hepatotoxins in mice.  This suggests that the 
activity of kolaviron on hepatotoxins comes from a byproduct of the metabolism 
of kolaviron in the liver, rather than from the direct inactivation of the hepatotoxin 
by kolaviron itself (Iwu 1987). 
Kolaviron was also found to be effective at protecting against another 
hepatotoxin called paracetamol.  Paracetamol, also referred to as acetaminophen, 
poisons the liver by depleting intracellular glutathione.  A key function of 
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glutathione is reducing the oxidizing agent N-acetyl-p-benzoquinoneimine 
(NAPQI), a metabolite formed by cytochrome P-450 mixed function oxidase.  If 
there is not a sufficient amount of glutathione to detoxify NAPQI, the NAPQI will 
covalently bond to cell macromolecules, resulting in cell death.  When rats were 
pretreated with kolaviron prior to paracetamol poisoning, the rate of lethality was 
very significantly reduced.  It has therefore been suggested that kolaviron, or one 
of the byproducts of the metabolism of kolaviron, may act as an inhibitor to 
cytochrome P-450 mixed function oxidase, or it may reduce the NAPQI itself 
(Akintonwa and Essein 1990). 
 Hepatitis C is a liver disease that chronically affects between 130-150 
million people globally.  It is caused by the acquisition of the hepatitis C virus, 
which is a blood borne, positive strand, enveloped RNA virus usually spread by 
unsafe injection practices.  There are six different genotypes of the virus, and 
treatment is dependent on which genotype the patient has (“Hepatitis C”). The 
infection can be either acute or chronic.  The acute infection can be asymptomatic 
and between 15-30% of people who are infected are able to clear the virus without 
any treatment within six months (“Viral Hepatitis- Hepatitis C Information”).  
However, the remainder of those infected will proceed to develop the more 
serious, chronic hepatitis C infection.  
Of those who develop the chronic hepatitis C infection, 15-30% will 
develop cirrhosis within twenty years and a significant number will develop liver 
cancer.  Annually, between 350,000- 500,00 people die from hepatitis C related 
liver diseases, and no vaccine is available.  Antiviral treatments, which can help 
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prevent cirrhosis and liver cancer caused by hepatitis C, are successful in between 
50-90% of those treated, but the treatment is not widely available and access to 
diagnosis is low.  Hepatitis C is most concentrated in Africa and Asia, though it is 
present worldwide (“Hepatitis C” 2015).  
 
Figure 4: Chronic hepatitis C infection global prevalence (reprinted from Holmburg 
2012) 
 
 In recent years, there has been great progress in the treatment of hepatitis 
C.  Before 2011, there were only two FDA approved drugs that treated hepatitis 
C. These medications were generally prescribed together, and less than one half of 
patients receiving this treatment achieved a sustained virologic response 
(McCarthy 2010).  The first drug in this regimen was called pegylated interferon.  
Pegylated interferon is an injection that contains a protein, IFN- α/β, that activates 
natural killer cells so that they have a greater cytotoxic potential to fight hepatitis 
C infections (Chung 2008). The second drug in the regimen is ribavirin, which 
acts by enhancing the response of hepatic genes to IFN- α/β (Chung 2008).  Since 
new drugs have come to market, however, pegylated interferon and ribavirin are 
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being phased out in favor of more effective drugs that can treat a wider variety of 
patients (“Advances in Medications to Treat Hepatitis C” 2015).  
One of the major advancements in hepatitis C treatment came in 2013 
when a once daily pill called Sofosbuvir (brand name Sovaldi) made it to market.  
Sofosbuvir is a NS5B polymerase inhibitor that treats HCV genotypes one, two, 
three, and four. The NS5B protein is essential for HCV viral replication, making it 
a useful target. Its structure contains a uridine analog that, when activated by 
triphosphorylation by hepatic enzymes in the liver, simulates the uridine 
nucleotide therefore competitively blocking the NS5B polymerase at the binding 
site for uridine.  This inhibits the RNA synthesis of the hepatitis C virus by 
causing chain termination (Bhatia 2014).  Sofosbuvir was also the first hepatitis C 
drug that could treat patients with hepatitis C and HIV co-infections. 
Unfortunately, Sovaldi costs approximately $1000 per pill, making the total cost 
for a twelve-week regimen about $84,000 (“Advances in Medications to Treat 
Hepatitis C” 2015).   
Another advancement in hepatitis C treatment came in 2014 with another 
once daily pill called Harvoni.  Harvoni combines sofosbuvir with another drug 
called Ledipasvir (“Advances in Medications to Treat Hepatitis C”).  Ledipasvir is 
an inhibitor of the NS5A protein produced by the hepatitis C virus (Lim 2014).  
Its exact mechanism of action is unclear, though evidence supports that ledipasvir 
directly binds to the hepatitis C viral protein NS5A (Kwon 2015). Harvoni only 
treats hepatitis C genotype one. Like Sovaldi, it is expensive; each pill costs 
$1125.  It is prescribed on an 8 or 12-week regimen, making the total cost of 
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treatment with Harvoni between $63,000 and $94,500.  Fortunately, it is very 
effective; Harvoni cured 94% of people of their hepatitis C infections after 12 
weeks of treatment in clinical trials (“Advances in Medications to Treat Hepatitis 
C” 2015). 
 
Figure 5: Structure of Ledipasvir 
 
 
 
Figure 6: Structure of Sofosbuvir 
 
 
 
Other effective treatments, such as Viekira Pak, Technivie, and Daklinza 
have also come to market since 2014.  Viekira Pak is a combination of 4 drugs: 
ombitasvir, paritaprevir, ritonavir, and dasabuvir. It blocks the HCV NS3/4A 
protease complex and the HCV NS5A protein ("Viekira Pak, 
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Ombitasvir/paritaprevir/ritonavir plus Dasabuvir." 2016). Ritonavir has no 
activity itself against HCV, but rather it acts as a pharmokinetic enhancer.  It 
helps to increase the concentration of one of the other drugs, paritaprevir.  
Ombitasvir acts as a NS5A protein inhibitor, and paritaprevir acts as an inhibitor 
to the NS3/4A protease. Lastly, Dasabuvir inhibits the NS5B polymerase.  
(Ombitasvir, paritaprevir/ritonavir plus dasabuvir (Viekira Pak) 2015). 
 Technivie is made of ombitasvir, paritaprevir, and ritonavir. Viekira Pak, 
Daklinza, and Technivie have similar shortcomings as Sovaldi and Harvoni; they 
only treat certain genotypes of hepatitis C and they are cost prohibitive.  Viekira 
Pak costs $83,320 for a twelve-week regimen.  When used in conjunction with 
ribavirin, which it often is, the cost increases to $85,820.  In addition, it cannot 
treat patients with advanced cirrhosis.  Technivie only treats genotype four, 
cannot treat patients with cirrhosis, and costs $76,653 for a 12 week regimen (plus 
$2500 for ribavirin which is usually prescribed with it). One of the newest drugs, 
daclatasvir (brand name Daklinza), is a direct acting antiviral that treats genotype 
three (“Advances in Medications to Treat Hepatitis C” 2015).  Like ledipasvir, it 
is an antiviral that acts directly on the NS5A HCV protein, though it acts on a 
different site on the protein than ledipasvir (Lim 2014).  It costs $63,000 for a 
twelve-week regimen, but it is prescribed with Sovaldi, which costs $84,000 for a 
twelve-week regimen (“Advances in Medications to Treat Hepatitis C” 2015).   
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Figure 7: Daklinza structure 
 
 
Figure 8: Ombitasvir structure 
 
Figure 9: Paritaprevir structure 
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Figure 10: Ritonavir structure 
 
 
Figure 11: Dasabuvir structure 
 
Though effective, these treatments present two very serious problems: cost 
and availability.  The regions of the world most affected by hepatitis C are in 
Africa as well as central and eastern Asia.  Despite the fact that nearly 90% of 
patients could be cured of their HCV infections if given the correct treatments, 
there are still about 500,000 people who die every year due to HCV related 
conditions (“Hepatitis C” 2015). Therefore, a need exists to explore more cost 
effective treatments so that the populations most in need of hepatitis C treatments 
can have affordable access to them.  Fortunately, Garcinia kola is widely 
cultivated in Africa, where the highest prevalence of HCV infections are 
estimated to be, and it is administered orally for its antihepatotoxic effects 
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(Akintonwa and Essein 1990).  In addition, the seeds are edible and they are 
considered “megadoses” of kolaviron (Iwu 1987).  
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II. Experimental 
 
 
Garcinia kola fractions were prepared according to two separate procedures.  
Fractions from both procedures were sent off for DCT bioassay.  
 
 
i.  First Procedure 
 
 To begin, two 750 g samples of Garcinia kola were blended in a 
commercial blender to a sand-like consistency.  One sample, to be referred to as 
the “dry sample,” was left under a fume hood for one week.  The other sample, 
the “wet sample,” was not left under the hood.  Both samples were gravity filtered 
with 500 mL of hexane, chloroform, ethanol, and water, in that order.  Each 
filtrate was collected and saved, then dried down using rotary evaporation until of 
all the solvent had evaporated.  The fractions were then photographed and 
weighed.   
 
Figure 12: Fractions prior to rotary evaporation. From left to right: ethanol fraction, hexane 
fraction, chloroform fraction, water fraction 
 
Following being photographed and weighed, each crude extract underwent 
solid phase extraction using silica cartridges.  To accomplish this, 25 mg of each 
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extract was collected, placed in a silica cartridge, and vacuum filtered with the 
following compositions of solvents in order: 
100% Hexane 
50:50 Hexane: Ethyl Acetate 
100% Ethyl Acetate 
50:50 Ethyl Acetate: Methanol 
100% Methanol 
100% Water 
 
However, following the solid phase extraction of the hexane crude extract, 
it was observed that the majority of the extract was still present in the silica 
cartridge after all of the solvents had passed.  It was decided that a more complete 
gradient of polarity could help pass a greater amount of the crude extract through 
the silica cartridge.  This led to a modification of the solvent compositions in an 
effort to maximize the yield of extracted molecules in the filtrate.  The new 
procedure consisted of the following solvent compositions: 
100% Hexane 
75:25 Hexane: Ethyl Acetate 
50:50 Hexane: Ethyl Acetate 
25:75 Hexane: Ethyl Acetate 
100% Ethyl Acetate 
75:25 Ethyl Acetate: Methanol 
50:50 Ethyl Acetate: Methanol 
25: 75 Ethyl Acetate: Methanol 
100% Methanol 
50:50 Methanol: Water 
100% Water 
 
This new procedure did appear to increase the mass of the crude extract 
that passed through the silica cartridge into the filtrates during solid phase 
extraction, so it was used for the subsequent solid phase extractions of the 
chloroform, ethanol, and water crude extracts.  Each of the filtrates were dried 
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down using rotary evaporation until the solvent had evaporated.  For several of 
these samples, 2 mg was weighed and sent off for DCT bioassay. 
  
  
 
 
 
ii. Second Procedure 
  
A 2.26 kg batch of Garcinia kola seeds arrived and some slight 
modifications were made to the procedure. The Garcinia kola seeds were placed 
in a grinder rather than a blender, and they were ground to a powder like 
consistency. The solvents used in gravity filtration for the crude extraction were 
also revised.  In chronological order, the solvents used in the second procedure 
consisted of hexane, ethyl acetate, ethanol, and a 50:50 mixture of ethanol and 
water. Rather than being immediately gravity filtered after blending, the Garcinia 
kola seeds were covered in each respective solvent, sonicated in a hot water bath 
at 42 oC for 30 minutes, vacuum filtered, sonicated at 42 oC for 30 minutes again, 
and finally vacuum filtered again.  This procedure was repeated for each of the 
four solvents.   
                           
Figure 13: Ethanol fra                                     Figure 14:(left to right) Ethanol precipitate, ethyl acetate partition, ethanol 
partition  
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The ethanol fraction required slightly different treatment because a 
precipitate (visible in figure 6) was present.  To collect the precipitate, the liquid 
portion of the fraction was decanted, leaving the precipitate with minimal solvent.  
Rotary evaporation was then performed on the precipitate portion to remove the 
remaining solvent.  The liquid portion of the ethanol sample was partitioned with 
ethyl acetate, creating two distinct layers that were then separated using a pipette.   
 
Figure 15: Ethanol fraction after partitioning 
 
Each extract was photographed and weighed.  Finally, 2 mg of each of the 
extracts was collected and sent for DCT bioassay. Once the results of the bioassay 
were obtained, it was noted that the crude hexane extract had the most promising 
biological activity against hepatitis C.  Due to this observation, the crude hexane 
extract was chosen to undergo further study.  Column chromatography was 
performed on the crude hexane extract using a 10% gradient of hexane: ethyl 
acetate in an attempt to purify it.  The fractions resulting from the column 
chromatography were then collected, weighed, and imaged using NMR 
spectroscopy. 
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Figure 16: Hexane crude extract during column chromatography with a 10% gradient of hexane: 
ethyl acetate 
 
 
Figure 17: Garcinia kola fractionation scheme 
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III. Results 
 
 The crude extract with the most promising biological activity against HCV 
infections of the samples that were tested was the hexane crude extract produced 
from the second procedure discussed in the Experimental section.  Due to this 
activity, the hexane extract was further fractionated using column 
chromatography, then the fractions were imaged using NMR spectroscopy. 
Table 1: Masses of first procedure Garcinia kola crude 
extracts 
Crude 
Extract 
Wet 
Sample 
Mass 
Dry 
Sample 
Mass 
Hexane 0.2531 g 0.2802 g 
Chloroform 0.8989 g 1.1965 g 
Ethanol 7.5858 g 3.0464 g 
Water 2.9499 g 0.9314 g 
 
Table 2: Mass of second procedure Garcinia kola crude 
extracts 
Crude Extract Mass 
Hexane 3.9992 g 
Ethyl Acetate 17.57 g 
Ethanol (Precipitate) 5.8231 g 
Ethanol (Ethanol Partition) 12.8398 g 
Ethanol  (Ethyl Acetate Partition) 10.368 g 
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Table 3: Biological activity of Garcinia kola fractions on hepatitis C 
      % Inhibition 
Fraction 
DC
t 
HC
V 
DCt 
rRN
A HCV 
rRN
A 
Hexane crude 
extract 
0.7
2 0.47 39.09 
27.5
6 
Ethyl acetate 
crude extract 
-
0.6
5 
-
0.28 -56.25 
-
21.4
9 
Ethyl Acetate 
Partition of 
Ethanol Fraction 
-
0.2
2 
-
0.13 -16.35 
-
9.52 
Precipitate of 
Ethanol Fraction 
-
0.1
3 0.41 -9.34 
24.5
0 
Ethanol fraction 
-
0.4
4 0.06 -35.45 3.84 
Water crude 
extract, filtered 
through silica 
with 75:25 ratio 
of Hexane: Ethyl 
acetate 
-
0.4
5 
-
0.28 -36.71 
-
21.4
9 
Water crude 
extract, filtered 
through silica 
with 50:50 ratio 
of Hexane: Ethyl 
acetate 
-
0.3
5 
-
0.82 -27.29 
-
75.6
2 
Water crude 
extract, filtered 
through silica 
with 25:75 ratio 
of Hexane: Ethyl 
acetate 
-
0.2
7 
-
0.03 -20.72 
-
2.21 
Ethanol crude 
extract, filtered 
through silica 
with 75:25 ratio 
of Hexane: Ethyl 
acetate 
-
0.4
4 
-
0.24 -35.14 
-
17.9
0 
Ethanol crude 
extract, filtered 
through silica 
with 50:50 ratio 
of Hexane: Ethyl 
acetate 
-
0.4
6 
-
0.28 -37.66 
-
21.6
3 
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Figure 18: NMR spectrum of 100% hexane fraction of Garcinia kola hexane crude extract 
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Figure 19: NMR spectrum of 9:1 hexane: ethyl acetate fraction of Garcinia kola hexane crude 
extract 
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Figure 20: NMR spectrum of 8:2 hexane: ethyl acetate fraction of Garcinia kola hexane crude 
extract 
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Figure 21: NMR spectrum of 7:3 hexane: ethyl acetate fraction of Garcinia kola hexane crude 
extract 
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Figure 22: NMR spectrum of 6:4 hexane: ethyl acetate fraction of Garcinia kola hexane crude 
extract 
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IV. Discussion 
 
 Hexane was the only crude extract that showed biological activity against 
hepatitis C.  In the DCT bioassay, the hexane crude extract at a concentration of 
10 μg/ml exhibited an inhibitory effect on the HCV antigen and rRNA of 39.09% 
and 27.56%, respectively.  Having identified the fraction with the most biological 
activity against hepatitis C, the next objective was to identify the specific 
compound in the crude extract that was responsible for the activity. However, 
attempting to isolate this molecule resulted in many obstacles.  Column 
chromatography was used in an attempt to separate the hexane crude extract into 
its individual constituents.  This eluted ten new fractions, however it was clear 
from the NMR data that the fractions were not completely pure.  In analyzing the 
NMR spectra, each of the fractions appeared to consist of multiple molecules.  
Therefore, it was impossible to hypothesize a single structure from the spectra 
because multiple compounds were being measured.  In addition, there appeared to 
be “bleed over” in the spectra, meaning that the spectra that were adjacent in the 
hexane: ethyl acetate gradient appeared to have similar peaks in the NMR spectra. 
This is most likely because some of the molecules that were soluble at one given 
solvent ratio on the gradient were also somewhat soluble at the adjacent solvent 
ratios on the gradient.  Therefore, the same molecules were able to appear in 
multiple NMR spectra, which resulted in striking similarities between some of the 
spectra.  
 While the identity of the unknown molecule(s) contributing to the hepatitis 
C biological activity cannot be ascertained with certainty from the NMR spectra 
 31 
or bioassay, there is evidence to support that the cause of the hepatitis C activity 
could be kolaviron.  
 The evidence supporting kolaviron as the source of the biological activity 
is largely coincidental.  There exists a published procedure to extract kolaviron 
from Garcinia kola.  In the procedure, Garcinia kola seeds are peeled, sliced, 
pulverized, and dried at 40 oC.  Following this drying, the Garcinia kola seed 
powder is extracted with petroleum ether in a soxhlet extractor for 24 hours.  
Having been defatted from the soxhlet extraction, the remains of the crushed 
seeds are then repacked and extracted with acetone.  This marc is then 
concentrated and diluted to two times its volume using water and finally extracted 
with ethyl acetate (Iwu 1985).  The procedure that was carried out in this 
experiment differed from the accepted procedure for the isolation of kolaviron.   
Petroleum ether, the solvent used to defat the Garcinia kola seeds in the published 
procedure, has the same polarity index (0.1) as hexane.  Because a soxhlet 
extraction is necessary to defat the kolaviron before it is extracted, it seems 
reasonable that the kolaviron may be in some way associated with the lipids 
present in the Garcinia kola seed.  Therefore, a possible explanation for the 
presence of biological activity in the hexane fraction is that the kolaviron is 
associated with lipids in the Garcinia kola seed, which causes it to be moderately 
soluble when extracted with hexane.   
 Another reason that kolaviron is a candidate for the biological activity 
against hepatitis C is its known antihepatotoxic effects across multiple 
hepatotoxins.  Orally administered kolaviron has been shown to combat multiple 
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hepatotoxins that have different modes of action, including paracetamol, 
galactosamine, carbon tetrachloride, phalloidin, and α-amanitin.  Notably, 
galactosamine poisoning mimics some features of hepatitis, and kolaviron has 
significant protective effects against galactosamine injury.  However, without a 
bioassay of isolated kolaviron, it is impossible to identify the constituent 
containing hepatitis C activity with certainty. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
 
V. Citations 
Adebisi, Atilade Akanmu. "A case study of Garcinia kola nut production-to-
consumption system in J4 area of Omo forest reserve, South-west Nigeria."Forest 
products, livelihoods and conservation: case studies of non-timber forest product 
systems 2 (2004): 115-132. Web. 2 Mar. 2016. 
 
"Advances in Medications to Treat Hepatitis C." Hep C 123. American Liver 
Foundation, Sept. 2015. Web. 1 Mar. 2016. 
 
Akinpelu, D. A., et al. "Biocidal activity of partially purified fractions from 
methanolic extract of Garcinia kola (Heckel) seeds on bacterial 
isolates."Biological research 41.3 (2008): 277-287. Web. 8 Mar 2016. 
 
Akintonwa, Alade, and Ani R. Essien. "Protective effects of Garcinia kola seed 
extract against paracetamol-induced hepatotoxicity in rats." Journal of 
ethnopharmacology 29.2 (1990): 207-211. Web. 14 Mar 2016. 
 
Bhatia, Harmeet Kaur et al. “Sofosbuvir: A Novel Treatment Option for Chronic 
Hepatitis C Infection.” Journal of Pharmacology & Pharmacotherapeutics 5.4 
(2014): 278–284. PMC. Web. 1 Apr. 2016. 
 
  
34 
34 
Chung, Raymond T. et al. “Mechanisms of Action of Interferon and Ribavirin in 
Chronic Hepatitis C: Summary of a Workshop.” Hepatology (Baltimore, Md.)47.1 
(2008): 306–320. PMC. Web. 18 Mar. 2016. 
 
Ferenčíková, R., Z. Červinková, and Z. Drahota. "Hepatotoxic effect of D-
galactosamine and protective role of lipid emulsion." Physiol Res 52 (2003): 73-
78. Web. 19 Mar. 2016.  
 
Holmberg S. Hepatitis C. In: CDC Health Information for International Travel 
2012 (yellow book). Oxford, UK: Oxford University Press, 2012:186–7. Web. 11 
Mar. 2016.  
 
Iwu, Maurice M., et al. "Evaluation of the antihepatotoxic activity of the 
biflavonoids of Garcinia kola seed." Journal of ethnopharmacology 21.2 (1987): 
127-138. Web. 3 Mar. 2016. 
 
Iwu, M.M. (1985) Antihepatotoxic Constituents of Garcinia kola seeds. 
Experientia 41, 699- 700. Web. 5 Mar. 2016. 
 
"Hepatitis C." WHO. World Health Organization, 2015. Web. 
<http://www.who.int/mediacentre/factsheets/fs164/en/>. 27 Feb. 2016.  
 
 35 
Kwon, Hyock Joo et al. “Direct Binding of Ledipasvir to HCV NS5A: 
Mechanism of Resistance to an HCV Antiviral Agent.” Ed. Philippe A. Gallay. 
PLoS ONE 10.4 (2015): e0122844. PMC. Web. 1 Apr. 2016. 
 
Lim, Precious J., and Philippe A. Gallay. “Hepatitis C NS5A Protein: Two Drug 
Targets within the Same Protein with Different Mechanisms of Resistance.” 
Current opinion in virology 0 (2014): 30–37. PMC. Web. 11 May 2016. 
 
McCarthy, Jeanette J. et al. “Replicated Association between an IL28B Gene 
Variant and a Sustained Response to Pegylated Interferon and 
Ribavirin.”Gastroenterology 138.7 (2010): 2307–2314. PMC. Web. 18 Mar. 
2016. 
 
Okoko, Tebekeme. "In vitro antioxidant and free radical scavenging activities of 
Garcinia kola seeds." Food and chemical toxicology 47.10 (2009): 2620-2623. 
Web. 12 Mar. 2016. 
 
"Ombitasvir, Paritaprevir/ Ritonavir Plus Dasabuvir (Viekira Pak)." (n.d.): n. pag. 
National Drug Monograph. US Department of Veteran Affairs, 2015. Web. 7 May 
2016. 
 
"Viekira Pak, Ombitasvir/paritaprevir/ritonavir plus Dasabuvir." BioCenutry 
BCIQ. BioCentury BCIQ, 2016. Web. 01 May 2016. 
  
36 
36 
 
"Viral Hepatitis- Hepatitis C Information." Centers for Disease Control and 
Prevention. Centers for Disease Control and Prevention, 11 Mar. 2016. Web. 17 
Mar. 2016.  
